The objective of this post-hoc analysis of the LIGHT trial was to investigate the effectiveness and safety of NB vs. PL among patients with type 2 diabetes and overweight or obesity who report taking either a DPP-4i or a GLP1-RA. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.